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Fitness is a parameter used to quantify how well an organism adapts to its environment; in the present study, fitness is
a measure of how well strains of human immunodeficiency virus type 1 (HIV-1) replicate in tissue culture. When HIV-1
develops resistance in vitro or in vivo to antiretroviral drugs such as reverse transcriptase or protease inhibitors, its
fitness is often impaired. Here, we have investigated whether the development of resistance in vitro to a small
molecule CCR5 inhibitor, AD101, has an associated fitness cost. To do this, we developed a growth-competition assay
involving dual infections with molecularly cloned viruses that are essentially isogenic outside the env genes under
study. Real-time TaqMan quantitative PCR (QPCR) was used to quantify each competing virus individually via probes
specific to different, phenotypically silent target sequences engineered within their vif genes. Head-to-head
competition assays of env clones derived from the AD101 escape mutant isolate, the inhibitor-sensitive parental virus,
and a passage control virus showed that AD101 resistance was not associated with a fitness loss. This observation is
consistent with the retention of the resistant phenotype when the escape mutant was cultured for a total of 20
passages in the absence of the selecting compound. Amino acid substitutions in the V3 region of gp120 that confer
complete AD101 resistance cause a fitness loss when introduced into an AD101-sensitive, parental clone; however, in
the resistant isolate, changes elsewhere in env that occurred prior to the substitutions within V3 appear to compensate
for the adverse effect of the V3 changes on replicative capacity. These in vitro studies may have implications for the
development and management of resistance to other CCR5 inhibitors that are being evaluated clinically for the
treatment of HIV-1 infection.
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Introduction
The relative replication ability (ﬁtness) of a human
immunodeﬁciency virus type 1 (HIV-1) quasispecies is
governed by how individual clones ﬂuctuate in dominance
as they adapt to the host environment [1]. The relative ﬁtness
of two viruses in vitro is best estimated by head-to-head
competition experiments [2]. Additional selection pressures
(e.g., immune responses) inﬂuence HIV-1 replication in vivo,
but the ﬁtness of HIV-1 in peripheral blood mononuclear cell
(PBMC) cultures increased with the extent of viral diversity
within a cohort of infected people, and isolates from long-
term non-progressors were less ﬁt than ones from rapid
progressors [3]. A structured treatment interruption clinical
trial showed that HIV-1 ﬁtness also inﬂuences the magnitude
of viremia rebound and the set point [4].
When HIV-1 develops resistance to the reverse tran-
scriptase and protease inhibitors, its ﬁtness is typically
impaired [2,5], which helps explain how beneﬁcial effects of
therapy can occur even when HIV-1 replication is incom-
pletely suppressed and highly resistant variants are present
[6–9]. Resistance to a fusion inhibitor, enfuvirtide (T-20), has
been associated with an in vitro ﬁtness reduction in some
[10,11], but not all, studies [12,13]. The instability of resistance
when T-20 is discontinued suggests that resistance mutations
impair ﬁtness in vivo [14].
The CCR5 inhibitors are a new class of compounds for
treating HIV-1 infection and include maraviroc (UK-427,857)
and vicriviroc (SCH-D), which are now in phase II/III trials.
Resistance to these inhibitors, as to any other antiviral agent
[15,16], will inevitably develop during therapy. We have
generated several CCR5 inhibitor–resistant isolates and
clones in cell culture systems [17–19]. Our best-characterized
variants were derived from the HIV-1 primary isolate CC1/85
under the selection pressure of AD101, a precursor of
vicriviroc. AD101 resistance is conferred by four amino acid
substitutions in the gp120 V3 region; the resistant viruses
continue to enter primary CD4
þ T cells via CCR5 by utilizing
the AD101-CCR5 complex [17,19,20]. Resistance of CC1/85 to
maraviroc occurs via a similar mechanism [21].
We have investigated whether resistance to AD101 in vitro
carries a ﬁtness cost by using a new dual-infection growth-
competition assay. This system employs molecularly cloned
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outside the env genes under study, but which can be
quantiﬁed individually using TaqMan quantitative PCR
(QPCR). We found that the AD101-resistant Envs were no
less ﬁt than those from the parental isolate. Accordingly, the
escape mutant remained AD101-resistant during 20 passages
in culture in the absence of the selecting compound.
Results
Replication Kinetics of Clonal, Env-Chimeric AD101-
Resistant and AD101-Sensitive Viruses
We generated clonal, Env-chimeric parental and AD101-
resistant viruses by a standard method in which the env gene
of the pNL4–3 infectious molecular clone [22] is replaced by
one of interest [17]. We previously used this system to make
Env-chimeric viruses containing env genes from parental and
AD101-resistant variants of the CC1/85 primary isolate; the
chimeras possess the co-receptor usage and entry inhibitor
sensitivity properties conferred by the inserted env gene [17].
We assessed the replication kinetics of a representative clone
of each virus by measuring the rate of p24 antigen production
in separate cultures of the same PBMC preparations. In the
absence of AD101, the wild-type clone CC1/85 cl.7 and the
AD101-resistant variant CC101.19 cl.7 replicated at compa-
rable rates and to similar extents (Figure 1). The resistant
virus also replicated comparably (;25 ng/ml of p24 after 8 to
9 d) in the presence of 1 lM AD101, a concentration that
completely inhibited p24 production by CC1/85 cl.7 (Figure
1). The high-level AD101 resistance of CC101.19 cl.7 was not,
therefore, associated with any apparent reduction in repli-
cation efﬁciency. However, comparing replication rates in
different mono-infection cultures does not always allow the
identiﬁcation of signiﬁcant differences in replicative ﬁtness
[2,23,24]. Better discrimination can be achieved when both
viruses replicate in the same culture. We therefore developed
an assay that could accurately quantify the replication of two
different clonal, Env-chimeric viruses in the same culture.
Development and Validation of a TaqMan QPCR–Based
Replicative Fitness Assay
The main challenge in determining the outcome of dual-
infection growth-competition experiments is to devise a
strategy to detect the two competing viruses without
introducing any changes in other regions of the HIV-1
genome that could potentially affect ﬁtness. We therefore
created sequence tags for virus detection by altering 11
nucleotides between positions 5466 and 5493 of pNL4–3, a
region containing only the vif open reading frame. The
changes create a stretch of synonymous mutations that do not
affect the Vif protein sequence, do not overlap the central
termination sequence [25], and do not signiﬁcantly interfere
with RNA secondary structure. Probes were designed for
speciﬁc annealing to either the wild-type (vifX) or the silent-
mutated (vifY) vif sequences under the conditions of a
TaqMan QPCR assay (Figure 2A). A standard plasmid
carrying tandem copies of both the vifX and vifY vif
sequences was constructed to serve as a template for
standardizing QPCR results when both TaqMan probes target
their speciﬁc sequences. Seven 10-fold serial dilutions of a
known molar concentration of this plasmid were used to
generate standard curves in every QPCR experiment. The
relationship between the plasmid copy number and the
QPCR threshold cycle (CT) value was log-linear, and the
plasmid standard was efﬁciently detected, the sensitivity limit
being ,50 copies of plasmid DNA per reaction (Figure 2B;
unpublished data). The average PCR efﬁciency for detection
of the vifX and the vifY sequences was 91% and 95% for the
six representative vifX and vifY multiplexed assays shown in
Figure 2B, respectively.
We inserted the env genes of the parental clone CC1/85 cl.7
and its AD101-resistant variant CC101.19 cl.7 into the vifY
version of pNL4–3 (Table 1). These vifY-containing clones
were used as references against which all the vifX-containing
viruses were competed. We always report ﬁtness differences
Figure 1. Replication Kinetics of Clonal, Env-Chimeric Viruses with an
AD101-Sensitive or an AD101-Resistant env Gene
The amount of p24 produced from PBMC culture infected with equal
titers of CC1/85 cl.7 (squares) or CC101.19 cl.7 (circles), in the absence
(filled symbols) or presence (open symbols) of 1 lM AD101, was
determined at the indicated time points. Duplicate wells were used to
derive each experimental value in each experiment, and the data shown
are the average 6 standard error of the mean (SEM) of values from five
independent experiments.
doi:10.1371/journal.ppat.0030079.g001
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Author Summary
When human immunodeficiency virus type 1 (HIV-1) develops
resistance in vitro or in vivo to antiretroviral drugs such as reverse
transcriptase or protease inhibitors, its replicative fitness is often
impaired (i.e., it grows at a lower rate or to a lesser extent than the
parental, inhibitor-sensitive virus). Here, we investigated whether
resistance development in vitro to a new class of antiretroviral
drugs, the CCR5 inhibitors, has an associated fitness cost. These
inhibitors, exemplified by the AD101 compound, are small
molecules that bind CCR5, a cell surface protein that HIV-1 uses as
a co-receptor during the process of cellular entry. We performed
direct-competition assays using sequence-labeled, clonal viruses
derived from an AD101 escape mutant, the AD101-sensitive parental
isolate, and a passage control isolate, and found that AD101
resistance was not associated with a fitness loss. Furthermore, when
the escape mutant was cultured for 20 passages without AD101, it
remained resistant. Specific amino acid substitutions conferring
AD101 resistance did cause a fitness loss when experimentally
introduced into a sensitive clone, but in the naturally selected
escape mutant they are probably compensated for by other
changes. This work may help understand the development and
management of resistance to CCR5 inhibitors now being evaluated
clinically to treat HIV-1 infection.in terms of the replication of the vifX virus relative to the vifY
reference. A plasmid expressing NL4–3 env and containing
the vifY sequence was also made to serve as a reference virus
in some experiments (Table 1).
We tested the assay’s speciﬁcity by using the vifX and vifY
probes to simultaneously detect their target sequences in
DNA ampliﬁed from cells infected with only one virus.
Separate PBMC cultures were infected with either the vifX or
vifY versions of the CC1/85 cl.7 or CC101.19 cl.7 clones, and
the vifX and vifY sequences were detected simultaneously
using the multiplexed QPCR assay (Figure 2C). Only the vif
allele present in the virus used to inoculate each culture was
ever detected; the average DNA copy number per QPCR
reaction derived from the cognate probe was typically .10
4,
Figure 2. The Use of the TaqMan QPCR Assay to Determine Replicative Fitness
(A) The sequences (39 to 59) of the vifX and vifY TaqMan probes are shown on top, the sequences of the vifX and vifY vif alleles are shown below. Each
probe differs from its target sequence by one nucleotide because the vifX probe was designed to match the consensus for HIV-1 subtype B vif in this
region. Each probe binds to the sense strand of proviral DNA. The probes are aligned to the target sequences with bars indicating positions of identity.
The two probes and the two vif alleles differ at 11 nucleotides each. The vifY vif allele that was engineered to tag the reference viruses contains only
synonymous changes.
(B) The plot demonstrates the working range and reproducibility of the QPCR assay. The average threshold cycle (CT) values obtained in six
representative multiplexed assays are shown 6 standard deviation (SD). In each assay, seven serial dilutions of the standard plasmid ranging from 53
10
7 to 5310
1 DNA templates were measured using TaqMan probes specific either for the vifX (Cy5 fluorescence, top panel), or the vifY sequence (FAM
fluorescence, bottom panel). The correlation coefficients (R
2) of the two standard curves were .0.995 and the PCR efficiencies were .90%.
(C) The specificity of the QPCR assay is depicted. Four independent PBMC cultures were singly infected with one of the CC1/85 cl.7 or the CC101.19 cl.7
viruses containing either the vifX or the vifY vif sequence. Genomic DNA from each culture was PCR amplified and then used in the multiplexed TaqMan
QPCR assay, as described in Materials and Methods. The average number of copies of each vif allele detected per QPCR reaction for each of the four
mono-infections from six representative experiments is shown 6 SEM. The lower limit for copy number is set to 100 for plotting purposes, although 50
copies can be quantified reproducibly, and the allele that was not present in the infection was never detected in any quantifiable amount in singly
infected cultures.
(D) The vif tag has no effect on replicative fitness. Competitive replication assays were performed in which viruses bearing the NL4–3 (circles), CC1/85
cl.7 (squares), or CC101.19 cl.7 (triangles) env genes and the vifX vif allele were competed against viruses bearing the same env genes but the vifY
sequence. The fitness differences (WD) at each indicated MOI were calculated as described in Materials and Methods. The calculated fitness differences
of each vifX virus relative to the vifY virus in each experiment are depicted, with the bar showing the mean value of three or four independent
experiments. A fitness difference of 1 arises when the two competing viruses are of equal replicative fitness; a value , 1 indicates that the virus with
vifY had the greater replicative fitness, . 1 that the virus with vifX was fitter.
doi:10.1371/journal.ppat.0030079.g002
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HIV-1 Resistance without Fitness Lossbut from the non-cognate probe, ,50 (Figure 2C). We
routinely use single-infection cultures as speciﬁcity controls
and have never detected the vif allele not known to be present
in these cultures (unpublished data).
In each set of competition assays, the two viruses were
added to PBMC cultures at the same multiplicity of infection
(MOI), 0.0001. In an otherwise identical culture, each virus
was also added at a higher MOI, 0.0005. In additional cultures,
one virus was present at an MOI of either 0.0001 or 0.0005,
the other in 10-fold excess. The resulting average copy
numbers detected per QPCR reaction were then used to
determine the proportion of each virus present in each test
culture on day 10 (NL4–3) or day 14 (CC1/85 cl.7 or CC101.19
cl.7) (see Materials and Methods). The relative proportions of
each virus at each condition were determined and the ﬁtness
difference (WD) value was calculated for each MOI, as
described elsewhere [3]. Under these experimental condi-
tions, WD is an approximation of the fold difference in the
replication ability of the two viruses added to a dual-infection
culture. The WD value is reported as the ﬁtness of the virus
bearing the vifX allele relative to a reference virus containing
vifY.
To determine if the vif tag could inﬂuence viral ﬁtness and
affect the outcome of head-to-head competitions in dual-
infection cultures, we established competitions with two
viruses with the same Env protein (NL4–3, CC1/85 cl.7 or
CC101.19 cl.7) but a different vif allele (i.e., vifX or vifY). The
WD values were always ;1; that is, there was no consistent
pattern of victory or defeat (Figure 2D). In addition, when vif
was sequenced from cultures mono-infected for 10 d with the
modiﬁed (vifY) version of NL4–3, it was unchanged (unpub-
lished data). Hence, as intended, the vif tag does not affect
ﬁtness. The extent of assay-to-assay variation in this type of
experiment also indicates that WD values differing by ,3-fold
are not meaningful (Figure 2D; unpublished data); conversely,
WD values .3o r,0.33 indicate that two viruses present in
direct-competitionassayshavedifferentreplicationcapacities.
Hence, we have developed a sensitive and speciﬁc assay to
quantify the replication of two different clonal viruses in the
same growth-competition culture.
Replication and Replicative Fitness of AD101-Resistant
and AD101-Sensitive Clonal Viruses
We used the assay to determine whether there was a
difference in replicative ﬁtness between AD101-resistant and
AD101-sensitive viruses. We ﬁrst measured the replication of
R5 clonal, Env-chimeric viruses (Table 1) in PBMC mono-
cultures for 14 d, using the TaqMan assay as an endpoint
(Figure 3). Every virus yielded a reproducible copy number
when tested at an MOI of 0.0005. All three AD101-sensitive,
parental CC1/85 clones were inhibited when 1 lM AD101 was
added 1 h prior to infection, the average copy number
reduction ranging from 33- to 480-fold for the different
clones. The AD101-sensitive CCcon.20 cl.11 passage control
clone was also strongly inhibited by AD101, with a 990-fold
reduction in copy number.
In contrast, the clones from the CC101.19 isolate were
AD101 resistant; there were no signiﬁcant differences in copy
numbers between the AD101-treated and control cultures,
even at inhibitor concentrations of 20 lM, and at either MOI
(Figure 3; unpublished data). The experimentally mutated
clone CC1/85 cl.7 (V3), which contains four amino acid
changes in V3 conferring complete AD101 resistance [17], was
also strongly AD101 resistant (Figure 3). The CC1/85 cl.7 (HP)
clone was inhibited by AD101, but the copy number
reduction was only 9-fold, substantially less than the 480-fold
reduction seen with the parental CC1/85 clone from which
CC1/85 cl.7 (HP) was derived by introducing the H308P
substitution. The H308P polymorphism, also present in CC1/
85 cl.8, was very rapidly selected for by AD101 and confers
partial resistance in a conventional, PBMC-based assay (i.e., a
5- to 10-fold shift in IC50) [17]. Thus, the pattern of resistance
of the various clones in the QPCR-based assay qualitatively
reproduces the phenotypes the infectious, replication-com-
petent viruses display in a standard virus production assay
[17].
Table 1. Nomenclature and Properties of Viruses Used in This
Study
Virus Isolate
[Reference]
Type env Clone vif Tag
CC1/85 [17] Parental CC1/85 cl.6 vifX
CC1/85 cl.7 vifX and vifY
CC1/85 cl.8 vifX
CC101.19 [17] AD101-resistant CC101.19 cl.3 vifX
CC101.19 cl.7 vifX and vifY
CC101.19 cl.15 vifX
Engineered from
CC1/85 [17]
AD101-resistant CC1/85 cl.7 (V3)
a vifX
Partially AD101-resistant CC1/85 cl.7 (HP)
b vifX
CCcon.20 [36] Passage control CCcon.20 cl.11 vifX
NL4–3 [22] X4, TCLA
c NL4–3 vifX and vifY
aCC1/85 cl.7 (V3) contains the four amino acid changes in V3 (K305R, H308P, A316V,
G321E) that are necessary and sufficient for complete AD101 resistance.
bCC1/85 cl.7 (HP) contains only the H308P amino acid change that confers partial
resistance to AD101.
cTCLA ¼ T cell line adapted.
doi:10.1371/journal.ppat.0030079.t001
Figure 3. Replication of Clonal, Env-Chimeric Viruses in Singly Infected
Cultures
The extent of replication is shown as the mean copy number per QPCR
reaction 6 SEM from three to 47 independent, singly infected cultures.
AD101 was absent (shaded bars) or was present at 1 lM (open bars). The
initial MOI was 0.0005.
doi:10.1371/journal.ppat.0030079.g003
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HIV-1 Resistance without Fitness LossVariations in how viruses replicate in single-infection
cultures are not always true indications of replicative ﬁtness
differences [2,23,24]. We therefore performed competitive
ﬁtness assays in dual-infected cultures. Each of the clonal
viruses listed in Table 1 that bore a vifX allele was tested in a
competitive dual-infection experiment against the vifY-
bearing versions of both the AD101-sensitive virus CC1/85
cl.7 and the AD101-resistant virus CC101.19 cl.7. The
competition cultures were again established at two MOIs
(0.0001 and 0.0005) and at three ratios at each MOI (1:1, 1:10,
10:1). The fractional proportions of each virus present in
each culture were calculated, with the averages over multiple
experiments used to calculate WD values for the two test
viruses at each MOI [3].
In general, the AD101-sensitive clone CC1/85 cl.6 and the
engineered, partially AD101-resistant clone CC1/85 cl.7 (HP)
substantially out-competed each reference virus, replicating
10- to 86-fold better in the dual-infection cultures (Figure 4A
and 4B). In contrast, the AD101-resistant clone CC101.19 cl.3
and the engineered, AD101-resistant clone CC1/85 cl.7 (V3)
were consistently less ﬁt than either reference virus,
replicating 2.4- to 71-fold less well under all the various
conditions described in Figure 4A and 4B. CC1/85 cl.7 (V3)
did not replicate detectably in the presence of the CC101.19
cl.7 reference virus in any experiment, so no WD could be
calculated for this pairing; however, based on the known
parameters of the assay, the inference is that CC1/85 cl.7 (V3)
is .1,000-fold less ﬁt than CC101.19 cl.7. The relative ﬁtness
of the other AD101-resistant and AD101-sensitive clones all
fell within a spectrum, with some patterns evident. For
example, the AD101-sensitive clone CC1/85 cl.8 and the
AD101-resistant clones CC101.19 cl.7 and CC101.19 cl.15
were generally ﬁtter than CC1/85 cl.7 (parental) and
CCcon.20 cl.11 (passage control) (Figure 4A and 4B). There
was no correlation between the copy numbers produced after
14 d in single-infection cultures and the WD values
determined from dual-competition cultures (compare Figure
3 with Figure 4A and 4B). The paradoxical nature of this
ﬁnding reinforces the unreliability of judging HIV-1 ﬁtness
based solely on single-infection cultures [2,23,24].
Because similar patterns of relative ﬁtness differences were
seen regardless of the reference virus or MOI, we averaged
the ﬁtness differences derived for each test virus in the
various individual cultures to derive a replicative ﬁtness rank
order relative to an arbitrary reference point (Figure 4C). The
resulting ﬁtness differences spanned an ;1,050-fold range;
Figure 4. Replicative Fitness of the Clonal Env-Chimeric Viruses Relative to the CC1/85 cl.7 and CC101.19 cl.7 Reference Viruses
(A and B) The replicative fitness of each vifX clonal virus relative to the indicated vifY reference virus was calculated from the mean virus proportions
from three to seven independent competition experiments, and is shown for MOIs of (A) 0.0001 and (B) 0.0005. Fitness differences , 1 indicate the vifX
virus is less fit than the vifY reference virus, . 1 that the vifX virus is the more fit. The vifX viruses used were: CC1/85 cl.6 (open squares), CC1/85 cl.7
(open triangles), CC1/85 cl.8 (open diamonds), CC101.19 cl.3 (filled squares), CC101.19 cl.7 (filled triangles), CC101.19 cl.15 (filled diamonds), CCcon.20
cl.11 (open circles), CC1/85 cl.7 (HP) (X symbol), and CC1/85 cl.7 (V3) (filled circles).
(C) The plotted fitness differences were averaged between reference viruses and MOIs from (A) and (B). Thus, the fitness differences shown are all
relative to an arbitrary reference point (¼ 1.0). The three clones from the AD101-resistant CC101.19 isolate are shown in bold (C).
(D) Independent fitness difference determinations generate reproducible results. The WD values for CC1/85 cl.6 vifX relative to CC1/85 cl.7 vifY are
plotted for three individual experiments at the MOIs indicated. This pairing was chosen because of the large difference in fitness between them. The WD
values were determined from the proportion of each virus within a single experiment. The bars represent the means of these WD values (31 and 63 at
MOIs of 0.0001 and 0.0005, respectively). The same data were analyzed in (A) and (B) by taking the average of the proportions between the three
experiments before calculating the WD, thereby minimizing the influence of outliers. The WD values derived from (A) and (B) were 10 and 63 at MOIs of
0.0001 and 0.0005, respectively.
doi:10.1371/journal.ppat.0030079.g004
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HIV-1 Resistance without Fitness Lossthe two extremes represent viruses engineered from CC1/85
cl.7 to contain either one (CC1/85 cl.7 (HP), the most ﬁt) or
four amino acid changes in V3 (CC1/85 cl.7 (V3), the least ﬁt).
The ﬁtness spectra of the various naturally occurring AD101-
sensitive and AD101-resistant clones overlapped within this
range.
In theory, at high MOIs, recombination between a vifX and
a vifY virus with the site of recombination between the vif
gene and the env gene could confound our results. If this
happened, competitions in which the observed WD value was
very high or very low would be poorly reproducible. We
derived the data in Figure 4A and 4B by determining the
average relative virus proportions from at least three experi-
ments before calculating the WD value, thereby minimizing
the inﬂuence of outliers. In Figure 4D we reanalyzed the data
for one set of competitions (CC1/85 cl.6 vifX versus CC1/85
cl.7 vifY) by calculating the WD values within each individual
experiment. The average WD values shown in Figure 4D were
31 and 63 at MOIs of 0.0001 and 0.0005, respectively, and the
WD values derived from Figure 4A and 4B were 10 and 63 at
these respective MOIs. The similarity in outcome between the
two approaches suggests that outliers do not contribute
signiﬁcantly to the observed ﬁtness differences, implying that
recombination is not occurring in the cultures.
Replication and Replicative Fitness of AD101-Resistant
and AD101-Sensitive Viral Isolates
The above experiments suggest that AD101 resistance is not
necessarily associated with a replicative ﬁtness reduction
(Figure 4). However, all of these data sets were generated with
clonal, recombinant viruses that are identical outside env, and
not with the original uncloned isolates that emerged in the
resistance-selection experiments. Any analysis of these iso-
lates is complicated by the likelihood that additional sequence
changes occurred outside env while HIV-1 adapted to
prolonged culture in PBMCs. Although we thought it unlikely
that clonal bias had obscured any underlying ﬁtness differ-
ences, we tested the original resistant isolates to gain further
insights into the relative ﬁtness of the AD101 escape mutants.
The copy numbers obtained for each isolate after 14 d of
PBMC culture were similar when the vifX probe was used
(Figure 5A), but no copies were detectable with the vifY probe
(unpublished data). Thus, these isolates can be used as test
viruses in competitions against vifY-tagged references. As
expected, replication of the CC1/85 isolate, but not the
CC101.19 isolate, was impaired by 1 lM AD101 (Figure 5A).
The average copy numbers calculated for both isolates were
somewhat lower than those seen with the corresponding
clones under similar conditions (compare Figure 5A to Figure
3). This is not surprising since the latter are based on the
genomic backbone of NL4–3, a clone adapted for optimal
growth in cell culture [22].
Having shown that the QPCR assay can be used to study the
replication of the isolates on which the clones were based, we
examined the ﬁtness of the CC1/85 and CC101.19 isolates
relative to the vifY-tagged reference clones CC1/85 cl.7 and
CC101.19 cl.7 in head-to-head competitions without AD101.
The outcome of these assays allowed us to determine the
comparative ﬁtness of the two isolates. The replicative ﬁtness
of each isolate was always less than that of the corresponding
reference clone (WD , 1, Figure 5B). This is likely to be a
consequence of using pNL4–3 as a background vector into
which env genes are inserted to make chimeric viruses. NL4–3
has probably acquired several mutations outside env that
improve its ﬁtness in vitro, compared to primary isolates like
CC1/85 [22]. When CC1/85 cl.7 was used as the reference virus,
the AD101-resistant isolate CC101.19 was found to be 89- and
390-fold more ﬁt than the parental CC1/85 isolate at the
MOIs of 0.0005 and 0.0001, respectively. With CC101.19 cl.7
as reference, CC101.19 was 85- and 42-fold more ﬁt than CC1/
85 at the same two MOIs. The average of these four ﬁtness
difference estimates is ;150. Hence, if any sequence changes
outside env did arise during culture of CC101.19, they
improved its ﬁtness. A conservative conclusion is that the
development of AD101 resistance by CC101.19 has not come
at the price of a dramatic ﬁtness loss.
Stability of the AD101-Resistant Phenotype in the
Absence of the Inhibitor
If the acquisition of AD101 resistance caused a replicative
ﬁtness loss in PBMC cultures, the resulting AD101-resistant
isolate would revert to sensitivity when the cultures were
continued without the inhibitor. Because the above studies,
Figure 5. Replication and Replicative Fitness of the CC1/85 and CC101.19
Isolates
(A) PBMC cultures were singly infected with the indicated isolates at an
MOI of 0.0005 in the presence (open bars) or absence (shaded bars) of 1
lM AD101. The vifX vif probe was used in the TaqMan QPCR assay to
derive the copy number per QPCR reaction; the values shown are the
means 6 SEM from three independent experiments.
(B) The fitness differences of the isolates CC1/85 (open symbols) or
CC101.19 (filled symbols) as detected by the vifX probe are shown
relative to the indicated vifY reference viruses at MOIs of 0.0001 (squares)
or 0.0005 (triangles). The values are derived from the mean virus
proportions from three independent experiments.
doi:10.1371/journal.ppat.0030079.g005
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did not create an unﬁt virus, we hypothesized that any such
reversion would be slow, and might not even occur. We
reported that when the AD101-resistant isolate generated
after 22 passages in the presence of AD101 (CC101.22) was
cultured in PBMCs without AD101 for nine additional
passages (CC101.22R9), it remained highly AD101 resistant
[19]. We therefore returned the CC101.22R9 isolate to culture
in PBMCs for 11 additional passages, hence 20 in total,
without AD101. The AD101 sensitivity proﬁles of the CC1/85,
CC101.19, and CC101.22R9 isolates, and ones receiving 10, 15,
or 20 passages without AD101 (CC101.22R10, CC101.22R15,
and CC101.22R20, respectively), were determined (Figure 6).
All the isolates from the AD101-free culture remained
completely resistant to AD101 concentrations as high as 5
lM, whereas the parental CC1/85 isolate was inhibited in the
1–10 nM range. Hence the AD101-resistant phenotype is
highly stable, which is consistent with the conclusion that it is
not associated with any signiﬁcant decrease in replicative
ﬁtness in PBMC cultures.
The Effect of AD101 on the Fitness of AD101-Resistant
Clonal Viruses
Finally, we sought to determine whether AD101 affected
the replicative ﬁtness of AD101-resistant viruses; these viruses
are clearly drug-resistant and not drug-dependent, but does a
dose of the drug give them a boost? The standard QPCR assay
system cannot be used to determine the relative ﬁtness of a
single virus in the presence and absence of an inhibitor.
Instead, we used a vifY-tagged version of the X4 clone NL4–3
as a reference virus that is unaffected by AD101, a CCR5
inhibitor, because it uses CXCR4 for entry. The vifY-tagged
NL4–3 virus was competed against the AD101-resistant vifX-
tagged CC101.19 cl.7 clone in cultures either lacking or
containing AD101 at a concentration (20 lM) that saturates
CCR5 (Figure 7A). Because NL4–3 replicates very efﬁciently
in PBMC culture, we added AMD3100 (20 nM), a CXCR4
inhibitor speciﬁc to this virus (i.e., one that would not affect
the R5 virus CC101.19 cl.7), to reduce its replication rate to a
level comparable to that of its competitor in the dual-
infection cultures. This AMD3100 concentration had no
effect on the copy numbers of CC101.19 cl.7 determined in
single-infection cultures, nor did AD101 affect NL4–3
replication (unpublished data).
Under these conditions, in the absence of AD101, the
ﬁtness of CC101.19 cl.7 was indistinguishable (WD ;1.5) from
that of NL4–3 at either MOI, indicating that AMD3100 had
indeed adjusted the replication rate of NL4–3 to the intended
degree (Figure 7A; unpublished data). In the presence of 20
lM AD101, the corresponding ﬁtness differences were 12 and
Figure 6. AD101 Sensitivity of AD101-Resistant Isolates after Extensive
Passage in the Absence of AD101
PBMC cultures were infected with the parental isolate CC1/85 (open
squares), the resistant isolate CC101.19 (filled squares), or isolates
CC101.22R9 (filled diamonds), CC101.22R10 (filled triangles),
CC101.22R15 (filled circles), and CC101.22R20 (X symbol) from the
reversion cultures, in the presence of different concentrations of AD101.
The amount of p24 produced in each AD101-containing culture after 7 d
is shown as a percentage of that produced by the same isolate in the
absence of inhibitor. The values shown are the means of four
independent experiments 6 SEM.
doi:10.1371/journal.ppat.0030079.g006
Figure 7. The Effect of AD101 on the Fitness of Clonal, Env-Chimeric AD101-Resistant Viruses
(A) Replicative fitness differences in PBMCs after 14 d of culture were determined at MOIs of 0.0001 (open squares) or 0.0005 (open triangles) for the vifX
CC101.19 cl.7 virus relative to the vifY NL4–3 reference virus, in the presence of 20 nM AMD3100 and in the presence or absence of 20 lM AD101, as
indicated.
(B) Replicative fitness differences in PBMCs after 14 d of culture were determined at MOIs of 0.0001 (squares, circles) or 0.0005 (triangles, diamonds) for
the vifX CC101.19 cl.3 virus (squares, triangles) or the vifX CC101.19 cl.15 virus (circles, diamonds), relative to the vifY CC101.19 cl.7 reference virus, and
in the presence or absence of 20 lM AD101, as indicated. In both panels, the plotted values are derived from the mean virus proportions from three
independent experiments.
doi:10.1371/journal.ppat.0030079.g007
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CC101.19 cl.7 is 8.1- to 32-fold ﬁtter when AD101 (20 lM) is
present (Table 2); AD101 therefore modestly enhances the
replicative ﬁtness of the CC101.19 cl.7 clone.
To see whether the enhancing effect of AD101 was unique
to CC101.19 cl.7, dual-infection experiments were performed
in which the vifX vif-bearing clones CC101.19 cl.3 and
CC101.19 cl.15 were competed against vifY-tagged CC101.19
cl.7, with AD101 again either absent or present at 20 lM. We
showed above that CC101.19 cl.15 was ﬁtter than CC101.19
cl.7 in the absence of AD101, whereas CC101.19 cl.3 was less
ﬁt (Figure 4A and 4B). When AD101 was present, the existing
ﬁtness differences between CC101.19 cl.15 or CC101.19 cl.3
and CC101.19 cl.7 were only minimally altered. For example,
the ﬁtness of CC101.19 cl.15 relative to CC101.19 cl.7 was
increased by 1.9-fold at an MOI of 0.0001, but at an MOI of
0.0005 it was decreased by 1.7-fold; such changes are
insigniﬁcant (Figure 7B; Table 2). Similarly, when AD101
was present, the ﬁtness of CC101.19 cl.3 relative to the
CC101.19 cl.7 reference virus was increased by 2.8- and 1.3-
fold at the low and high MOIs. The AD101-resistant CC1/85
cl.7 (V3) virus was found not to replicate detectably when in
competition with the CC101.19 cl.7 reference virus, whether
AD101 was present or not; no ﬁtness differences could
therefore be calculated for this pairing (unpublished data).
Overall, we conclude that AD101 did not signiﬁcantly affect
pre-existing ﬁtness differences between the various
CC101.19-derived clones. A corollary is that, like CC101.19
cl.7, the ﬁtness of the AD101-resistant clones CC101.19 cl.15
or CC101.19 cl.3 is also increased when AD101 is present
during a 14-d PBMC culture (summarized in Table 2). Thus,
all the AD101-resistant viruses we tested are not just resistant
to the selecting compound, they actually replicate more
efﬁciently in its presence, albeit only to a modest extent that
may not always be apparent in conventional PBMC assays.
Discussion
How HIV-1 adapts to its environment can be quantiﬁed by
measuring its ability to produce infectious progeny (ﬁtness).
Fitness determinations can help us understand how HIV-1
adapts, either in vitro or in vivo, to selection pressures
imposed by antiretroviral drugs. Strains resistant to reverse
transcriptase or protease inhibitors are often less ﬁt than
their parents (reviewed in [2,5]). Similarly, resistance to
enfuvirtide is often associated with reduced ﬁtness in vitro or
in vivo in some [10,11,14,26,27], but not all [13], studies.
Resistance to the CXCR4 inhibitor AMD3100 in vitro also
incurs a ﬁtness cost [28]. We have been studying resistance to
small molecule CCR5 inhibitors in vitro, exempliﬁed by
AD101, a vicriviroc precursor whose development was
discontinued for pharmocokinetic reasons [17–20]. Here, we
have investigated the ﬁtness cost of AD101 resistance,
developing a new assay that may have general utility.
Assays of the in vitro replicative ﬁtness of drug-resistant
HIV-1 strains, or phenotypic variants in general, have become
increasingly sophisticated [10,13,29,30]. In particular, the use
of QPCR technology has simpliﬁed the procedure while also
improving the detection sensitivity for competing viral
variants [29,31–33]. Yet, limitations still exist. For example,
not all HIV-1 strains can be analyzed easily, because genetic
variation affects the binding sites for standard primers. Assay
precision can also be problematic, particularly when ﬁtness
differences are slight. And assay procedures cannot affect
viral ﬁtness; any probe sequences inserted into the genome
must be ﬁtness-neutral.
Our new assay involves detecting two different vif alleles in
the genomic DNA from PBMCs cultured with viruses tagged
with these sequences. The assay can detect as little as a 3-fold
ﬁtness difference between two viruses in a dual-competition
assay, and the genetic sequences detected by the probes have
no effect on ﬁtness (the probes detect wild-type and mutant
vif gene sequences that have no effect on the Vif protein or
other known functions of the genome). The method is
ﬂexible: the ﬁtness inﬂuence of any gene other than vif can
be tested by inserting it into the NL4–3 vifY virus and
competing the chimera against a relevant NL4–3 vifX clone.
This allows the ﬁtness impact of small genetic differences to
be assessed, without redesigning probes speciﬁc for each new
test virus. The method can also work with uncloned isolates,
because the vifX probe was designed to recognize a vif region
highly conserved among subtype B strains; here, we have
studied both clones and isolates.
Recombination is a concern with all dual-competition
ﬁtness assays, here speciﬁcally between the vifX- and vifY-
tagged viruses. The likelihood of this occurring probably
increases with the distance between the gene under study and
the probe-binding sequence in vif. We have used MOIs low
enough (0.0001 and 0.0005) to render recombination highly
improbable, based on previous studies [34,35]. The likelihood
of recombination between two viruses of equal ﬁtness is
estimated as , 1% per 1,000 nucleotides at an MOI of 0.001
[34]. As we have used even lower MOIs, it is unlikely that
enough dual-infected cells are present for recombination to
occur detectably. This view is supported by the reproduci-
bility of the ﬁtness differences we measured (see, for example,
Figure 4D); frequent recombination would create a much
wider scatter of results, with outliers.
We saw no correlation between ﬁtness differences (Figure
4) and the absolute copy numbers produced by the same
viruses in single-infection cultures (Figure 3). This reinforces
reports that replication rates in single-virus cultures are not
Table 2. Effect of 20 lM AD101 on the Fitness Differences of
AD101-Resistant Test Viruses Relative to the Indicated Reference
Viruses
Test Virus Reference Virus
CC101.19 cl. 7 NL4–3
(þ 20 nM AMD3100)
MOI ¼
0.0001
MOI ¼
0.0005
MOI ¼
0.0001
MOI ¼
0.0005
CC101.19 cl.7 N/A N/A 8.1 32
CC101.19 cl.3 2.8 1.3 23
a 42
a
CC101.19 cl.15 1.9 0.59 15
a 19
a
All values shown are the ratios of the fitness differences in the presence of 20 lM AD101
to those in the absence of AD101.
aThese values were inferred from the experiments shown in Figure 7, but not measured
directly.
N/A, not applicable.
doi:10.1371/journal.ppat.0030079.t002
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assays are the best way to assess the relative ﬁtness of
different viruses [2,23,24].
In Vitro Replicative Fitness of AD101-Resistant and
Passage Control env Clones
We have shown that an R5 primary isolate, CC1/85, becomes
highly resistant when serially passaged in PBMC culture with
increasing concentrations of AD101 [19]. A resistant isolate
from passage 19, CC101.19, remained CCR5-dependent for
replication in PBMC culture. Env sequence changes were
necessary and sufﬁcient to confer AD101 resistance, which
developed in two stages: a single amino acid polymorphism in
V3, H308P, was selected during the earliest passages with
AD101 and conferred modest (5- to 10-fold) resistance; three
de novo mutations, also in V3 (K305R, A316V, G321E), arose
later to produce a highly (.20,000-fold) resistant virus [17].
The H308P polymorphism increases the efﬁciency with which
HIV-1 can use low CCR5 levels for entry, whereas the later
changes create gp120 proteins that can recognize the
inhibitor-bound conformation of CCR5 [17,19,20].
When we commenced this study, several lines of evidence
suggested the AD101 escape mutants might not have reduced
ﬁtness relative to the parental and passage control isolates: (i)
The resistant phenotype as well as the underlying genetic
changes were stable, in the short-term, after the inhibitor-
selection pressure was withdrawn; (ii) the replication rates of
the CC1/85 and CC101.19 clones in primary CD4
þT cells were
similar; and (iii) the CC101.19 clones did not require AD101
for replication [17,19]. Our initial experiments supported
these ﬁndings (Figure 1).
We therefore used the dual-competition assay to compare
three env clones from both the parental CC1/85 and the
AD101-resistant CC101.19 isolates in the vifX background,
with vifY-tagged reference viruses containing env genes from
either CC1/85 cl.7 or CC101.19 cl.7. Three other env genes
inserted into vifX-tagged viruses were similarly studied: a
CC1/85 env engineered to contain the V3 H308P change (CC1/
85 cl.7 (HP)); a derivative of the same env containing all four
V3 changes that confer complete AD101 resistance (CC1/85
cl.7 (V3)); and an env cloned from the 20th-passage control
isolate (CCcon.20 cl.11) (Table 1). Using WD values averaged
over MOIs and reference viruses, with WD¼1 representing an
arbitrary reference point for comparisons, the three env
clones from CC1/85 spanned an ;50-fold range of ﬁtness
differences, as did the three CC101.19 clones. A critical point
is that these ranges overlapped each other, implying that
AD101 resistance in vitro caused no intrinsic ﬁtness loss
(Figure 4C).
The two extremes in the ﬁtness range are represented by
t h et w oe n g i n e e r e dv i r u s e s .T h es i n g l eH 3 0 8 Pc h a n g e
allowing CC1/85 cl.7 to use free CCR5 more efﬁciently
confers an ;50-fold ﬁtness increase when AD101 is absent.
Despite this, the minor H308P variant did not expand in
frequency in the passage control culture, for reasons that
have yet to be understood [17,20]. The three additional V3
changes that then permit use of the AD101-bound form of
CCR5 produce a virus ;20-fold less ﬁt than the parental CC1/
85 cl.7 clone. Compared, then, to the partially resistant single
mutant, the three later-arising substitutions responsible for
complete resistance cause an ;1,000-fold ﬁtness loss. We
note, however, that these engineered viruses are isogenic
elsewhere in env, whereas the original uncloned isolates and
the derivative clones are not. Hence, the ﬁtness loss
associated with the three later-arising V3 substitutions may
be compensated for by additional changes elsewhere in gp120
(or even in gp41); we previously noted the possible
importance of such compensatory changes [17,18]. However,
it is unlikely that any compensatory changes arose directly
from a selective pressure for increased ﬁtness, because V3 is
the only env region undergoing selection after the fourth
passage with AD101 [17]. Rather, we believe the V3 changes
arose in an Env context that was selected for early in the
escape process, and in that particular environment they cause
no ﬁtness reduction. These scenarios contrast markedly with
the ﬁtness effects associated with the pathways to protease
and reverse transcriptase inhibitor resistance; there, primary
resistance mutations affecting the action of the drug typically
confer a ﬁtness loss, but are compensated for by secondary
mutations that eventually restore ﬁtness [2].
We passaged a control isolate in PBMCs in the absence of
AD101 [36]. The resulting 19th passage isolate, CCcon.19, and
a related clone, CCcon.20 cl.11, became more sensitive to
soluble CD4 without any change in AD101 sensitivity, due to
slowly accumulating sequence changes in the V1/V2 region
[36]. We hypothesized that these passage control viruses had
mutated to improve their ﬁtness in the absence of counter-
selection by the neutralizing antibodies that are present in
vivo [36]. We now show that the ﬁtness of CCcon.20 cl.11 falls
within the range spanned by the various CC1/85 and
CC101.19 clones. As the V1/V2 changes accumulated slowly,
any ﬁtness differences they do impart may be too minor to be
quantiﬁed, and/or that more CCcon.20 env clones would need
to be studied to detect them. Genetic and phenotypic changes
during prolonged cultures of primary isolates in PBMCs have
now been described by others [21,37].
In Vitro Replicative Fitness of the AD101-Resistant Isolates
We have studied the ﬁtness of HIV-1 clones that are
identical outside env, whereas the uncloned isolates from our
original resistance-selection experiments may have had other
sequence changes inﬂuencing their phenotypes. Analysis of
these isolates is complicated by any sequence changes arising
as the virus adapts to extended culture in PBMCs, rather than
due to the effect of the CCR5 inhibitor. Even so, we
considered that studying the isolates could still be informa-
tive about gross ﬁtness changes, and might alleviate concerns
about whether the limited number of clones available for
study creates any clonal bias. Compared to either reference
virus (CC1/85 cl.7 or CC101.19 cl.7), the AD101-resistant
CC101.19 isolate had, on average, a WD value ;150-fold
higher than the parental CC1/85 isolate (Figure 5B). Even
though we cannot exclude an inﬂuence of the culture process
on ﬁtness, it does seem reasonable to conclude that AD101
resistance is not associated with a ﬁtness loss at the level of
either the uncloned isolates or the derivative clones.
A corollary of this conclusion is that AD101 resistance
should remain stable during extended in vitro passage in the
absence of the inhibitor. We showed that CC101.22, a
resistant isolate from passage 22 of the original AD101
selection culture, retained its phenotype during nine addi-
tional passages in the absence of AD101 [19]. Moreover, the
four V3 changes responsible for AD101 resistance also
remained stable over this time [17]. We have now cultured
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all, a total comparable with the 22 passages the virus had
received with AD101 present. Isolates from these cultures
remained highly AD101 resistant (Figure 6), strongly support-
ing the conclusion that complete resistance to AD101 does
not confer a signiﬁcant ﬁtness loss.
In contrast, another CCR5 inhibitor–resistant isolate,
generated under the selection pressure of SCH-C in PM1 cells
and derived from the subtype G strain JV1083, did gradually
reverttosensitivitywhenitwaspassagedforprolongedperiods
without SCH-C. The genetic pathway to reversion was similar,
butnotidentical,tothepathwaytoresistance,withV3changes
predominatinginbothinstances(J.Riley,L.Wojcik,W.Huang,
S. Xu, S. Kuhmann, et al., unpublished data). In another study,
two maraviroc-resistant isolates derived from the primary
isolates RU570 and CC1/85 were generated in PBMCs [21]. The
resistance of both viruses was associated with V3 changes, but
even when the same CC1/85 isolate was used in different
experiments, different genetic changes conferred resistance
[21]. After 20 passages without maraviroc, the resistant isolates
partially(CC1/85)orcompletely(RU570)revertedtosensitivity
[21].Overall,HIV-1canfollowdifferentgeneticroutestoresist
small molecule CCR5 inhibitors, pathways perhaps associated
with varying degrees of ﬁtness loss.
The Effect of AD101 on the Fitness of AD101-Resistant
Clones
How resistance to small molecule CCR5 inhibitors is
manifested can be both assay- and cell type–dependent [20].
When the replication-competent Env-chimera CC101.19 cl.7
was tested in a PBMC-based replication assay, the AD101-
related compound vicriviroc caused no inhibition, but rather
modestly but consistently enhanced p24 production. In
contrast, when the same env gene was used in a single round,
Env-pseudotype assay involving PBMCs, vicriviroc was parti-
ally inhibitory, the extent of inhibition plateauing at ;25%.
When the same Env-pseudotype virus was studied in U87-
CD4/CCR5 cells, an inhibition plateau was again observed,
but now at ;90% inhibition. We have concluded that
CC101.19 cl.7 can enter cells by using both the inhibitor-
bound and inhibitor-free forms of CCR5, and that the height
of the plateau, when it occurs, is a measure of the relative
efﬁciency with which the two CCR5 conﬁgurations are used, a
parameter inﬂuenced by the cell type [20]. Similar conclu-
sions have been drawn regarding maraviroc resistance [21].
To gain further insights, we investigated whether entry via
the AD101-bound form of CCR5 inﬂuences the ﬁtness of the
AD101-resistant clones, using a saturating AD101 concen-
tration (20 lM) to ensure that no free receptor remained on
the target cells. All three CC101.19-derived clones were ﬁtter
in the presence of AD101 than they were in its absence
(Figure 7; Table 2). This is mechanistically informative,
because HIV-1 entry is not enhanced by vicriviroc or
AD101 in single-round assays ([20]; unpublished data). As
the ﬁtness assays involve 14 d of replication in PBMC culture,
it seems likely that the ﬁtness increase conferred by AD101,
like the replication enhancement caused by vicriviroc, only
arises during multiple replication cycles; we are now
investigating why this occurs. One possible factor is that
CCR5 ligands like AD101 and vicriviroc can upregulate both
CCR5 and its chemokine ligands MIP-1b and RANTES in
PBMC cultures, events irrelevant for single-cycle entry assays
[20]. The interplay between the various CCR5 ligands
(chemokines, small molecule inhibitors, and gp120) during a
multi-cycle replication process is likely to be complex.
Implications for the Clinical Use of CCR5 Inhibitors to Treat
HIV-1 Infection
Two small molecule CCR5 inhibitors, maraviroc and
vicriviroc, are now in advanced clinical trials as therapeutics,
and cause signiﬁcant (;1.5 log10) viral load reductions [38,39].
As with all HIV-1 therapies, resistance development must be
anticipated [15,16]. The existing classes of antiretrovirals
sometimes provide continued therapeutic beneﬁt even when
resistance arises, and the drug-sensitive phenotype reemerges
when the selecting drug is withdrawn. These events are
hallmarks of a ﬁtness cost to resistance, suggesting that ﬁtness
decreasesmeasuredinvitrodohaveclinicalrelevance[2,14,27].
There are real limitations to in vitro assays when predicting
what might happen to HIV-1 in vivo, particularly for studies
involving the envelope glycoproteins [16]. These proteins face
multiple evolutionary pressures in vivo, conferred by neu-
tralizing antibodies, changes in the numbers and types of
target cells, alterations in the number and nature of their co-
receptors, and the presence of both natural (chemokine) and
unnatural (drugs, when present) co-receptor ligands. Most of
these selection pressures are absent in vitro, or else present as
uncontrolled variables (e.g., production of chemokine ligands
in PBMC cultures noted above). There are changes in the in
vitro sensitivity of CCR5 inhibitor-resistant viruses to certain
neutralizing monoclonal antibodies (P. Pugach and J. Moore,
unpublished data), but here again the in vivo situation will be
more complex.
If, however, our central observation—that some CCR5
inhibitor-resistant viruses are no less ﬁt than parental
strains—is directly relevant to what might happen in vivo,
the implication is that such viruses would persist for
prolonged periods after CCR5 inhibitor therapy is discon-
tinued. Although no inhibitor would then be present to
occupy CCR5, the resistant viruses are not ‘‘drug-dependent’’,
but can use the free receptor. One theoretical concern is that
the alteration in how resistant viruses utilize CCR5 could
enable them to use CCR5 conformational variants differently
or more efﬁciently, opening up additional target cells to
infection. HIV-1 variants with higher CCR5 afﬁnities and
lower sensitivities to CCR5 ligands can arise naturally during
HIV-1 infection, because of the drop in the average levels of
CCR5 available on target cells [40–44]; CCR5 inhibitor-
resistant variants might, in principle, have a similar advant-
age over wild-type viruses under certain conditions. None-
theless, naturally occurring viruses with complete resistance
to CCR5 inhibitors have rarely been observed ex vivo or in
vivo. Thus, whatever replication advantage might be con-
ferred by Env conﬁguration changes allowing use of the
CCR5-inhibitor complex, other counter-selection pressures
presumably prevent this from occurring naturally. Ex vivo
analyses of viruses derived from long-term clinical studies of
CCR5 inhibitors, together with the general experience gained
from these trials, might clarify some of the above issues.
Materials and Methods
Reagents. AD101 (SCH-350581) was provided by Julie Strizki
(Schering-Plough Research Institute, Kenilworth, New Jersey, United
States). The small molecule CXCR4 inhibitor AMD3100 was obtained
PLoS Pathogens | www.plospathogens.org June 2007 | Volume 3 | Issue 6 | e79 0729
HIV-1 Resistance without Fitness Lossfrom the National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program.
Viruses. Viruses used in the ﬁtness studies include the parental R5
isolate (CC1/85), the AD101-resistant isolate (CC101.19), and three
clonal, NL4–3/Env-chimeric infectious viruses derived from each of
these isolates (Table 1). Mutants of the one of the CC1/85 clones with
varying degrees of resistance include a virus with one amino acid
change in V3 (H308P) conferring partial AD101 resistance, and one
with all four V3 changes (K305R, H308P, A316V, G321E) necessary
and sufﬁcient for full resistance [17]; these clonal viruses are
designated ‘‘CC1/85 cl.7 (HP)’’ and ‘‘CC1/85 cl.7 (V3),’’ respectively.
Their construction and properties have been described [17,20]. A
clone from the passage 20 control isolate (CCcon.20 cl.11) [36] was
also studied. Clonal proviruses containing the mutated vif sequence
were constructed as below. Infectious virus stocks were prepared by
transient transfection of 293T cells with pNL4–3/env plasmids using
Lipofectamine 2000 (Invitrogen, http://www.invitrogen.com) accord-
ing to the manufacturer’s instructions, as described [17,20,36]. Stocks
of the CC1/85, CC101.19, and CC101.22R9 isolates were prepared as
described [19]. All infectious stocks were stored in aliquots at 80 8C.
The titers (50% tissue culture infectious dose [TCID50]) of all stocks
were determined in PBMC culture by standard methods [45].
Cell culture and extended virus passage. CD8-depleted PBMC
cultures were puriﬁed and stimulated as described [17,18,20]. PBMCs
from between two to four random donors were mixed in equal
proportions to reduce donor-dependent effects on viral replication.
After stimulation, PBMCs were maintained in lymphocyte medium
(RPMI 1640 þ 10% FBS þ 2 mM L-glutamine þ 100 U/ml IL-2). The
CC101.22R9 isolate [19] was returned to culture for 11 additional
passages in activated PBMC culture without AD101. Passages were
performed weekly by adding a 5-ml aliquot of culture supernatant
and cells from the previous passage to 15 ml of freshly stimulated
PBMCs at 2 3 10
6 cells/ml. The remaining supernatant was ﬁltered
and frozen in 1-ml aliquots at  80 8C for drug sensitivity testing.
Viral replication kinetics. To determine the growth kinetics, 100
TCID50 of the test virus were used to inoculate 2310
5 cells in 200 ll
of lymphocyte medium (MOI ¼ 0.0005) in replicate wells of a 96-well
plate. After incubation at 37 8C for the indicated times, duplicate
wells were harvested and virus was inactivated by addition of 1%
Empigen BB detergent (Sigma-Aldrich, http://www.sigmaaldrich.com).
All samples from a single experiment were tested simultaneously for
p24 antigen using an in-house ELISA [46]. Replication rates were
determined by plotting the increase in p24 antigen over time. The
sensitivities of isolates CC1/85, CC101.19, CC101.22R9, CC101.22R10,
CC101.22R15, and CC101.22R20 to inhibition by AD101 were assayed
as described previously [17]. Brieﬂy, PBMC cultures were infected in
96-well plates, as described above, in the presence of varying AD101
concentrations, then p24 concentrations were measured after 7 d.
Construction of pNL4–3 vif tracking vector and real-time PCR
standard. The ﬁrst step in the construction of the mutated pNL4–3 vif
tracking vector, pNL4–3 vifY, involved subcloning of the region of
pNL4–3 located between the SphI (position 1448) and EcoRI
(position 5744) restriction sites into pNEB193 (New England Biolabs,
http://www.neb.com). The resulting pNEB-NL4–3 was subjected to
site-directed mutagenesis using the Stratagene (http://www.stratagene.
com) Quickchange I kit and the following primers, as speciﬁed by the
manufacturer: HIV Vif Sense (59-CCA TAG AAT GGA GGA AAA
AGA GAT ATA GC-39), HIV Vif AntiS (59-GTT GCA GAA TTC TTA
TTA TGG C-39), HIV VifY B sense (59-AGC TTG CAA TAT CTA GCG
TTG GCA GCA TTA ATA AAA CCA AAA CAG-39), and HIV VifY B
AntiS (59-CAA CGA TAG ATA TTG CAA GCT TCC TAC CTT GTT
ATG TCC TGC-39) to form pNEB-NL4–3-vifY. The mutated SphI to
EcoRI fragment was sub-cloned back into pNL4–3 to form pNL4–3-
vifY and sequenced using the Vif Seq S primer (59-TGG CAA GTA
GAC AGG ATG AGG A-39). To construct the CC1/85 cl.7 and
CC101.19 cl.7 reference proviruses with the vifY allele, the env
sequence was removed from the appropriate pNL4–3-env plasmid
using the EcoRI and XhoI restriction sites, then ligated into the
corresponding sites in pNL4–3-vifY. We veriﬁed that the vifY
sequence in vif did not revert to the wild-type (vifX) form under
the conditions of growth-competition assays (unpublished data).
The QPCR standard was created by ﬁrst cloning the wild-type
NL4–3 vif (VifX) sequence into the pCR2.1 TOPO vector (Invitrogen),
using the HIV Vif Sense and HIV Vif AntiS primers described above,
to form pCR2.1-vifX. The wild-type vif sequence was then sub-cloned
from pCR2.1-vifX into pNEB-NL4–3-vifY using the EcoRI restriction
site. The plasmid, pVifStd, contained tandem copies of both the vifX
and vifY alleles. The concentration of this standard was quantiﬁed by
UV absorbance spectrophotometry. Ten-fold serial dilutions were
used as templates to generate standard curves in the real-time
TaqMan PCR assays.
Growth-competition assays. These were performed in 48-well
plates seeded with 2 3 10
6 stimulated PBMCs in 0.8 ml. The two
viruses under evaluation were added to the target cells at individual
MOIs of 0.0001 or 0.0005, which are generally accepted to be low
enough to prevent recombination [35]. Three competitions were
established for each pair at each MOI, using different ratios of the
input viruses (1:1, 1:10, and 10:1). When appropriate, inhibitors were
incubated with target cells for 1 h before virus addition. To limit the
inherent variability of PBMC replication assays, each data point was
derived from duplicate cultures on the same plate, and all experi-
ments were performed at least thrice. Additional controls included in
each experiment entailed mono-infections of PBMCs with each virus
separately at different MOIs (low or high) in the presence or absence
of various AD101 concentrations. Competition cultures involving X4
and R5 viruses were maintained for 10 and 14 d, respectively. The
cells were then harvested, washed once with phosphate-buffered
saline (PBS), and pelleted for DNA extraction using the QIAamp
DNA Blood Mini Kit, according to the manufacturer’s instructions
(Qiagen, http://www.qiagen.com).
TaqMan QPCR assay. Competition experiments were analyzed
using a multiplexed TaqMan PCR assay. First, 5 ll of extracted DNA
were subjected to a brief, external PCR ampliﬁcation reaction in a
ﬁnal volume of 25 ll, using the Vif subtype B S (59-TGG CAG GTG
ATG ATT GTG TGG CA-39) and Vif subtype B AntiS (59-GGT CTT
CTG GGG CTT GTT CCA TCT-39) primers and AccuPrime SuperMix
II, as speciﬁed by the manufacturer (Invitrogen). DNA ampliﬁcations
were performed under the following cycling conditions: 1 cycle at 94
8C for 2 min; 10 cycles at 94 8C for 30 s, 55 8C for 30 s, and 68 8C for 45
s; and 1 cycle at 68 8C for 2 min. The reaction product was then
puriﬁed using the QIAquick PCR Puriﬁcation Kit (Qiagen).
The TaqMan assay utilizes probes to differentiate between the two
forms of the NL4–3 backbone (vifX and vifY). The probes are labeled
with different ﬂuorescent markers at their 59-ends. In solution, prior
to binding of the primers and probes to their target sequences, and
during annealing, the quenching agent on the opposite end of the
probes dampens the ﬂuorophores’ signals. However, during the PCR
extension step, the probe becomes vulnerable to the 59 to 39
exonuclease activity of Taq DNA polymerase; freed from proximity
to the quencher, the ﬂuorophore can now emit a ﬂuorescence signal
that is ampliﬁed logarithmically by successive rounds of PCR and
monitored in real-time. The number of PCR cycles required to reach a
given threshold ﬂuorescence value is inversely proportional to the
logarithm of the input quantity of dsDNA containing the probe
sequence. By quantifying the ﬂuorescence output from both probes,
each competing viral genome can be quantiﬁed simultaneously from a
singlesample.Inthe assay,theBrilliant QPCRMaster Mix(Stratagene)
was used with the primers Vif beta S (59-AGT TAG TCC TAG GTG
TGA-39) and Vif beta AS (59-TCC ATC TGT CCT CTG TCA-39) and
the reference dye ROX, according to the manufacturer’s speciﬁca-
tions. Included in the reaction were the vifX and the vifY probes
(sequences are provided in Figure 2A) that were labeled with Cy5 and
Black Hole Quencher 2 (vifX), and with FAM and Black Hole
Quencher 1 (vifY) at the 59- and 39-ends, respectively. The reactions
were run on a Stratagene Mx4000 machine using the cycling
conditions: 95 8C for 10 min, then 95 8C for 30 s and 55 8C for 1
minfor 40 cycles. All reactions were performedin triplicate, including
theseven serialdilutionsofthestandardDNAtemplate, (rangingfrom
5310
7 to 5310
1 copies), as well as a negative control (no-template).
The meanvalues of the measured numbers of copiesper reactionwere
then determined using the Stratagene Mx4000 software version 4.20,
and used for further analysis. The slope and correlation coefﬁcient of
each standard curve were calculated based on the average threshold
cycle (CT) values measured in triplicate for each dilution point. The
PCR efﬁciency, E, was computed as (10
 1/s 1)3100%, where s is the
slope of the generated standard curve.
Calculation of viral ﬁtness. Fitness differences (WD) were calcu-
lated for each clonal virus based on its relative production in head-to-
head competition, as previously described [3]. Initially, the copy
numbers per QPCR reaction of the vifX and vifY alleles in each
infection well were determined from the triplicate QPCR reactions
for each infection condition; copy numbers for the duplicate
infection conditions were then averaged. The copy numbers of the
10:1 and 1:10 infections were weighted by their initial proportions in
the inoculum, and the weighted copy numbers from the three
conditions (1:1, 10:1, and 1:10) were averaged to give a single copy
number per experimental condition (nvifX and nvifY). The proportion
of each virus at each condition (wvifX and wvifY) was then determined
from the ratio of the copy number of that virus (nvifX or nvifY) to the
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HIV-1 Resistance without Fitness Losstotal copy number (wvifX ¼ nvifX/[nvifX þ nvifY] and wvifY ¼ nvifY/[nvifX þ
nvifY]). The ﬁtness difference (WD) for an individual experiment was
calculated by determining the ratio of these proportions, always
comparing the test vifX virus to the reference vifY virus (WD ¼ wvifX/
wvifY). Thus, when WD . 1, the vifX virus has won the competition,
and when WD , 1, the vifY virus has prevailed. When the WD value is
based on more than one experiment, the proportions (wvifx and wvifY)
from each experiment were averaged before calculating the WD value,
to avoid giving undue weight to any single experiment.
For WD values calculated from single experiments where the vifX
and vifY viruses had the same env gene (Figure 2D), the greatest
deviation from the expected WD value of 1 was 0.35. Thus, we
conservatively conclude that WD values .3o r,0.33 indicate that two
viruses in direct competition differ signiﬁcantly in their replication
capacities. If the minimum copy numbers per QPCR reaction
produced in mono-infected cultures was ;5 3 10
4 (it was frequently
higher) and the minimum copy numbers that could be detected is 50
(it was probably lower), then we would be able to detect ﬁtness
differences of up to 1,000-fold. Hence, using these conservative
estimates, we conclude that the working range for the assay is WD
values of 0.0001 to 1,000.
Supporting Information
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) ac-
cession numbers for CC1/85- and CC101.19-derived env clones used in
this study are CCcon.20 cl. 11 (AY357537), CC1/85 cl. 6 (AY357338),
CC1/85 cl.7 (AY357341), CC1/85 cl.8 (AY357344), CC101.19 cl.3
(AY357466), CC101.19 cl.7 (AY357465), and CC101.19 cl.15
(AY357468). The GenBank accession number of the plasmid pNL4–
3 containing the NL4–3 provirus is AF324493.
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